gemcitabine has been researched along with pyrimidin-2-one beta-ribofuranoside in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, J; Johnson, ZL; Kwon, DY; Lee, JH; Lee, K; Lee, M; Lee, SY | 1 |
| Leung, E; Lozano Hernandez, L; Reginald-Opara, JN; Svirskis, D; Tang, M; Wang, H; Wu, Z | 1 |
| Bhutkar, S; Dukhande, V; Patel, K; Patki, M; Saraswat, A | 1 |
3 other study(ies) available for gemcitabine and pyrimidin-2-one beta-ribofuranoside
| Article | Year |
|---|---|
Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters.
Topics: Animals; Bacterial Proteins; Binding Sites; Biological Transport; Crystallography, X-Ray; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Kinetics; Membrane Transport Proteins; Molecular Docking Simulation; Nucleoside Transport Proteins; Oocytes; Protein Binding; Quantitative Structure-Activity Relationship; Recombinant Proteins; Ribavirin; Substrate Specificity; Thermodynamics; Uridine; Vibrio cholerae; Xenopus laevis | 2014 |
Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery.
Topics: Animals; Cell Line, Tumor; Cytidine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Liposomes; Pancreatic Neoplasms; Rats | 2021 |
In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms | 2021 |